Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing investigation of Jivi (BAY 94-9027) in adult patients with hemophilia A
2018-003655-37Phase 4Completed
- Sponsor
- Bayer Consumer Health
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of damoctocog alfa pegol in hemophilia A, sponsored by Bayer Consumer Health. Primary endpoint: General safety of Jivi with focus on immunogenicity and inhibitor development. Started May 2019; status: completed.
02
Drugs
damoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2018-003655-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003655-37.